Saeed Sadeghi

Title(s)HS Clinical Professor, Medicine
SchoolMedicine
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Single center experience using stereotactic body radiation therapy (SBRT) on orthotopic liver transplant protocol for unresectable cholangiocarcinoma. HPB (Oxford). 2024 Mar; 26(3):444-450. Wu TC, Deng J, Chu FI, Sadeghi S, Finn R, Agopian VG, Lee P, Raldow AC. PMID: 38142182.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. HCC EV ECG score: An extracellular vesicle-based protein assay for detection of early-stage hepatocellular carcinoma. Hepatology. 2023 03 01; 77(3):774-788. Sun N, Zhang C, Lee YT, Tran BV, Wang J, Kim H, Lee J, Zhang RY, Wang JJ, Hu J, Zhang Z, Alsudaney MS, Hou KC, Tang H, Zhang TX, Liang IY, Zhou Z, Chen M, Yeh AH, Li W, Zhou XJ, Chang HR, Han SB, Sadeghi S, Finn RS, Saab S, Busuttil RW, Noureddin M, Ayoub WS, Kuo A, Sundaram V, Al-Ghaieb B, Palomique J, Kosari K, Kim IK, Todo T, Nissen NN, Tomasi ML, You S, Posadas EM, Wu JX, Wadehra M, Sim MS, Li Y, Wang HL, French SW, Lu SC, Wu L, Pei R, Liang L, Yang JD, Agopian VG, Tseng HR, Zhu Y. PMID: 35908246; PMCID: PMC9887095.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    3. Infigratinib for cholangiocarcinoma. Drugs Today (Barc). 2022 Jul; 58(7):327-334. Sadeghi S. PMID: 35851868.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    4. Radiation Therapy for Mantle Cell Lymphoma with Orbital Involvement. Radiol Imaging Cancer. 2022 07; 4(4):e220027. Savjani RR, Ati S, Sadeghi S, Bonelli L, Kaprealian TB, Hegde JV. PMID: 35866891; PMCID: PMC9358483.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    5. Circulating Tumor Cell-Based Messenger RNA Scoring System for Prognostication of Hepatocellular Carcinoma: Translating Tissue-Based Messenger RNA Profiling Into a Noninvasive Setting. Liver Transpl. 2022 02; 28(2):200-214. Lee YT, Sun N, Kim M, Wang JJ, Tran BV, Zhang RY, Qi D, Zhang C, Chen PJ, Sadeghi S, Finn RS, Saab S, Han SB, Busuttil RW, Pei R, Zhu Y, Tseng HR, You S, Yang JD, Agopian VG. PMID: 34664394; PMCID: PMC8820407.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    6. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2021 10; 6(10):803-815. Javle M, Roychowdhury S, Kelley RK, Sadeghi S, Macarulla T, Weiss KH, Waldschmidt DT, Goyal L, Borbath I, El-Khoueiry A, Borad MJ, Yong WP, Philip PA, Bitzer M, Tanasanvimon S, Li A, Pande A, Soifer HS, Shepherd SP, Moran S, Zhu AX, Bekaii-Saab TS, Abou-Alfa GK. PMID: 34358484.
      View in: PubMed   Mentions: 115     Fields:    Translation:HumansCTClinical Trials
    7. Covalent Chemistry-Mediated Multimarker Purification of Circulating Tumor Cells Enables Noninvasive Detection of Molecular Signatures of Hepatocellular Carcinoma. Adv Mater Technol. 2021 May; 6(5). Sun N, Lee YT, Kim M, Wang JJ, Zhang C, Teng PC, Qi D, Zhang RY, Tran BV, Lee YT, Ye J, Palomique J, Nissen NN, Han SB, Sadeghi S, Finn RS, Saab S, Busuttil RW, Posadas EM, Liang L, Pei R, Yang JD, You S, Agopian VG, Tseng HR, Zhu Y. PMID: 34212072; PMCID: PMC8240468.
      View in: PubMed   Mentions: 2  
    8. Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring. Nat Commun. 2020 09 07; 11(1):4489. Sun N, Lee YT, Zhang RY, Kao R, Teng PC, Yang Y, Yang P, Wang JJ, Smalley M, Chen PJ, Kim M, Chou SJ, Bao L, Wang J, Zhang X, Qi D, Palomique J, Nissen N, Han SB, Sadeghi S, Finn RS, Saab S, Busuttil RW, Markovic D, Elashoff D, Yu HH, Li H, Heaney AP, Posadas E, You S, Yang JD, Pei R, Agopian VG, Tseng HR, Zhu Y. PMID: 32895384; PMCID: PMC7477161.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansCells
    9. Hepatocellular Carcinoma-Circulating Tumor Cells Expressing PD-L1 Are Prognostic and Potentially Associated With Response to Checkpoint Inhibitors. Hepatol Commun. 2020 Oct; 4(10):1527-1540. Winograd P, Hou S, Court CM, Lee YT, Chen PJ, Zhu Y, Sadeghi S, Finn RS, Teng PC, Wang JJ, Zhang Z, Liu H, Busuttil RW, Tomlinson JS, Tseng HR, Agopian VG. PMID: 33024921; PMCID: PMC7527695.
      View in: PubMed   Mentions: 46     Fields:    
    10. Somatic copy number profiling from hepatocellular carcinoma circulating tumor cells. NPJ Precis Oncol. 2020; 4:16. Court CM, Hou S, Liu L, Winograd P, DiPardo BJ, Liu SX, Chen PJ, Zhu Y, Smalley M, Zhang R, Sadeghi S, Finn RS, Kaldas FM, Busuttil RW, Zhou XJ, Tseng HR, Tomlinson JS, Graeber TG, Agopian VG. PMID: 32637655; PMCID: PMC7331695.
      View in: PubMed   Mentions: 8  
    11. Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial. Future Oncol. 2020 Oct; 16(30):2375-2384. Makawita S, K Abou-Alfa G, Roychowdhury S, Sadeghi S, Borbath I, Goyal L, Cohn A, Lamarca A, Oh DY, Macarulla T, T Shroff R, Howland M, Li A, Cho T, Pande A, Javle M. PMID: 32580579.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    12. Systemic Therapy for Primary Liver Tumors: Cholangiocarcinoma and Hepatocellular Carcinoma. Surg Oncol Clin N Am. 2019 10; 28(4):695-715. Sadeghi S, Bejjani A, Finn RS. PMID: 31472914.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    13. A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinoma. Liver Transpl. 2018 07; 24(7):946-960. Court CM, Hou S, Winograd P, Segel NH, Li QW, Zhu Y, Sadeghi S, Finn RS, Ganapathy E, Song M, French SW, Naini BV, Sho S, Kaldas FM, Busuttil RW, Tomlinson JS, Tseng HR, Agopian VG. PMID: 29624843; PMCID: PMC6097911.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCells
    14. Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer. Lung Cancer. 2018 09; 123:91-98. Garon EB, Siegfried JM, Stabile LP, Young PA, Marquez-Garban DC, Park DJ, Patel R, Hu EH, Sadeghi S, Parikh RJ, Reckamp KL, Adams B, Elashoff RM, Elashoff D, Grogan T, Wang HJ, Dacic S, Brennan M, Valdes Y, Davenport S, Dubinett SM, Press MF, Slamon DJ, Pietras RJ. PMID: 30089602; PMCID: PMC6118115.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    15. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. J Clin Oncol. 2018 01 20; 36(3):276-282. Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA, Chen LT, Reungwetwattana T, Van Cutsem E, Yeh KH, Ciombor K, Finn RS, Patel A, Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK, Bekaii-Saab T. PMID: 29182496; PMCID: PMC6075847.
      View in: PubMed   Mentions: 265     Fields:    Translation:HumansCTClinical Trials
    16. Determination of hepatocellular carcinoma grade by needle biopsy is unreliable for liver transplant candidate selection. Liver Transpl. 2017 09; 23(9):1123-1132. Court CM, Harlander-Locke MP, Markovic D, French SW, Naini BV, Lu DS, Raman SS, Kaldas FM, Zarrinpar A, Farmer DG, Finn RS, Sadeghi S, Tomlinson JS, Busuttil RW, Agopian VG. PMID: 28688158.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    17. Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 Patients. AJR Am J Roentgenol. 2017 Oct; 209(4):722-732. Gomes AS, Monteleone PA, Sayre JW, Finn RS, Sadeghi S, Tong MJ, Britten CD, Busuttil RW. PMID: 28705059.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    18. Stereotactic body radiotherapy (SBRT) for locally advanced extrahepatic and intrahepatic cholangiocarcinoma. Adv Radiat Oncol. 2016 Oct-Dec; 1(4):237-243. Sandler KA, Veruttipong D, Agopian VG, Finn RS, Hong JC, Kaldas FM, Sadeghi S, Busuttil RW, Lee P. PMID: 28740893; PMCID: PMC5514222.
      View in: PubMed   Mentions: 19  
    19. Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine. Pharmgenomics Pers Med. 2014; 7:329-38. Sadeghi S, Olevsky O, Hurvitz SA. PMID: 25378946; PMCID: PMC4207068.
      View in: PubMed   Mentions: 4  
    20. Metastatic human epidermal growth factor 2 (HER2/neu) amplified breast cancer with acute fulminant hepatitis responding to trastuzumab, pertuzumab and carboplatin. BMJ Case Rep. 2014 Jun 04; 2014. Macias MN, Shin DS, Ledezma B, Sadeghi S. PMID: 24899001; PMCID: PMC4054489.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    21. Systemic therapy for cholangiocarcinoma. Clin Liver Dis (Hoboken). 2014 Apr; 3(4):86-89. Sadeghi S, Finn RS. PMID: 30992893; PMCID: PMC6448706.
      View in: PubMed   Mentions:
    22. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol. 2011 Oct 10; 29(29):3877-84. Eiermann W, Pienkowski T, Crown J, Sadeghi S, Martin M, Chan A, Saleh M, Sehdev S, Provencher L, Semiglazov V, Press M, Sauter G, Lindsay MA, Riva A, Buyse M, Drevot P, Taupin H, Mackey JR. PMID: 21911726.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansCTClinical Trials
    23. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009 Nov 20; 27(33):5538-46. Johnston S, Pippen J, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M. PMID: 19786658.
      View in: PubMed   Mentions: 341     Fields:    Translation:HumansCTClinical Trials
    24. Characteristics of indolent non-Hodgkin lymphoma in patients with type 1 human immunodeficiency virus infection. Cancer. 2002 Mar 01; 94(5):1500-6. Levine AM, Sadeghi S, Espina B, Tulpule A, Nathwani B. PMID: 11920507.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    With one click, see people who:

    Run Clinical Trials

    See more options in the Advanced Search tab

    Saeed's Networks
    Concepts (148)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (45)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California